1 E-cigarette use and Respiratory Symptoms in Residents of the United States: A BRFSS Report

- 2
- 3 Marcia H. Varella¹, Olyn A. Andrade^{2&}, Sydney M. Shaffer^{2&}, Grettel Castro^{1&}, Pura Rodriguez^{1&}, Noël C.
- 4 Barengo^{1,3,4¶}, Juan M. Acuna^{56¶*}
- ¹Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International
 University, Miami, FL, USA
- 7 ²American University of Antigua College of Medicine
- 8 ³Department of Health Policy and Management, Robert Stempel College of Public Health and Social Work,
- 9 Florida International University, Miami, FL, USA
- ⁴Department of Public Health, Faculty of Medicine, University of Helsinki, Finland
- ⁵Khalifa University, CMHS, Department of Epidemiology and Public Health. RDISC Aw 8474000331 AD,
 UAE
- ⁶ CRUSADA, Robert Stempel College of Public Health and Social Work, Florida International University,
 Miami, FL, USA
- 15 [¶] These authors contributed equally to this work.
- 16 & These authors also contributed equally to this work.
- 17 * Corresponding author: Juan.acuna@ku.ac.ae

18

19 Abstract

20	Purpose: E-cigarettes are the most common type of electronic nicotine delivery system in the United States,				
21	rapidly gaining presence worldwide. E-cigarettes contain numerous toxic compounds that have been shown				
22	to induce mild to severe structural damage to the airways. The objective of this study is to assess if there is an				
23	association between e-cigarette use and respiratory symptoms in adults in the US as reported in the BRFSS in				
24	an attempt to drive potential early detection and prevention of severe or permanent respiratory disease.				
25	Methods: We analyzed data from 18,079 adults, 18-44 years, who participated at the Behavioral Risk Factor				
26	Surveillance System (BRFSS) in the year 2017. E-cigarette smoking status was categorized as current				
27	everyday user, current some days user, former smoker, and never smoker. The frequency of any respiratory				
28	symptoms (cough, phlegm, or shortness of breath) was compared. We calculated unadjusted and adjusted				
29	odds ratios (OR) and 95% confidence intervals (CI).				
30	Results: The BRFSS reported prevalence of smoking e-cigarettes was 6%. About 28% of the participants				
31	reported any of the respiratory symptoms assessed. The frequency of reported respiratory symptoms was				
32	highest among current some days e-cigarette users (45%). After adjusting for selected participant's				
33	demographic, socio-economic, and behavioral characteristics, and asthma and COPD status, the odds of				
34	reporting respiratory symptoms increased by 49% among those who use e-cigarettes some days (OR 1.49;				
35	95% CI: 1.06-2.11), and by 29% among those who were former users (OR 1.29; 95% CI: 1.07-1.55)				
36	compared with those who never used e-cigarettes. No statistically significant association was found for those				
37	who used e-cigarettes every day (OR 1.41; 95% CI 0.96-2.08)				
38	Conclusion: E-cigarettes cannot be considered safe alternatives to combustible traditional cigarettes. Cohort				
39	studies may shed more evidence on the association between e-cigarette use and specific respiratory diseases.				
40	Key words: E-cigarettes; Respiratory symptoms; Cough; Phlegm; Shortness of Breath; Lung disease; Young				

41 adults; Behavioral Risk Factor Surveillance System

43 Introduction

44	E-cigarettes use, or vaping was considered a safer alternative to conventional cigarettes and a potential
45	alternative in tobacco smoking cessation efforts (1-3). It was introduced in the US marketplace in 2007 and
46	since then its use has grown exponentially. Estimates based on the 2016-2017 Behavioral risk Factor
47	Surveillance System (BRFSS) indicate a 4.4% prevalence of e-cigarette use for adults (18 years or older) (4,5)
48	According to the National Youth Tobacco Survey (NYTS), e-cigarette use in 2020 for middle and high school
49	students was estimated to be about 19.6 % and 4.7%, respectively (6).
50	The increase in the use of e-cigarettes is of concern. While e-cigarettes may reduce regular cigarette
51	use, e-cigarette aerosol contains several toxic chemical constituents, including diacetyl or benzaldehyde, that
52	negatively affect the respiratory system. (7,8). E-cigarette is also associated with wheezing, chronic cough,
53	phlegm, or bronchitis in children and adults. (9-11). The results of a recently published systematic review
54	estimated that the pooled OR associated with e-cigarette use for asthma was 1.39 (95% confidence interval
55	(CI) 1.28-1.51) and for COPD was 1.49 (95% CI 1.36-1.65) (12).
56	While growing evidence points to detrimental respiratory effects of e-cigarettes use, just a few
57	comparative studies assessed the effects of e-cigarettes in population-based, community-dwelling adults in the
58	US(13-15). Additionally, the impact of e-cigarettes on the respiratory system has been assessed mainly by the
59	report of asthma and or COPD, which could have underestimated the magnitude of the respiratory effects
60	caused by e-cigarettes.

In this study, we assessed the association between e-cigarette use and the occurrence of respiratory
 symptoms (namely cough, phlegm production, or shortness of breath) as reported in the BRFSS, to obtain a
 more comprehensive understanding of the previous potentially underestimated impact of e-cigarette use in
 adults in the United States.

65 Methods

66 Design and setting

We used data from the 2017 BRFSS. Briefly, the BRFSS is an ongoing national yearly cross-sectional
survey, originally aimed to identify emerging health problems to modify public health programs and policies.
(16) It consists of phone-based interviews regarding participants' health-related risk behaviors, chronic health
conditions, and use of preventive services. The inclusion criteria consisted of individuals between the ages of
18-44 and those living within Arizona, the District of Columbia, Florida, Georgia, Minnesota, Nevada,
Tennessee, and West Virginia. Only these states in the US collected information on the outcome of interest.

73 Study variables

74 E-cigarette usage (or vaping) was categorized as current everyday e-cigarette smokers, current someday ecigarette smokers, former smokers, and those that never smoked, according to self-report. The outcome of 75 interest was the presence of respiratory symptoms, considered present if the participant reported any of the 76 following: cough, phlegm production occurring daily in the past three months, or shortness of breath hurrying 77 on level ground or when walking up a slight hill or stairs. No report of these three symptoms was considered 78 79 as an absence of the outcome. Covariates assessed included participant's age (assessed as a continuous variable and also categorized as either 18-34 or 35-44 years old), sex, race (White, Black, Hispanic, and 80 "other"), employment status (employed, unemployed, student, and unable to work), education level (less than 81 high school, high school graduate/General Educational Development exam completion, up to 3 years of 82 college, and greater than 4 years of college), family yearly income ($\leq 15,000, >15,000$ to 25,000, >25,000 to 83 35,000 > 35,000-50,000, and > 50,000), marital status (married and unmarried), health insurance status 84 85 (insured and uninsured), exercise reported in the past 30 days (yes, no), cigarette smoking status (current, former, never smoker), and history of ever being told to have asthma or chronic obstructive pulmonary 86 disease. 87

88 Statistical analysis

89	A descriptive analysis was conducted to assess overall sample characteristics and to check for missing data
90	patterns. Subsequently, bivariate analyses were done to further assess for potential confounders in the sample.
91	Lastly, unadjusted and adjusted logistic regression analysis were conducted to estimate crude and adjusted
92	odds ratios and corresponding 95% confidence intervals to explore and control for potential confounding
93	variables and to determine potential interactions (effect modifiers). STATA v15 software was used for all
94	analyses. ¹¹ Further analyses restricted to participants who were never smokers and to those never reporting
95	having asthma and COPD were performed.

96 This study does not require IRB clearance as it uses publicly available data from the CDC BRFSS.

97 Results

Of the 22,844 participants who completed the BRFSS questionnaire in the selected states in 2017, 98 18,079 participants met our study inclusion criteria and were assessed. Table 1 displays the characteristics of 99 participants according to e-cigarette use categories. Overall, never users of e-cigarettes were more frequently 100 older, females, of minority race/ethnicity (African American and Hispanics), married, of higher education 101 102 achievement (> 4 years of college) and higher income compared to all other e-cigarette users categories. 103 Never users also reported less frequently smoking of traditional (combustible) cigarettes. For most comparisons, differences were more striking between never users and everyday e-cigarette users. The 104 105 frequency of asthma and COPD report were highest for those who e-cigarettes use frequency was reported as "some days". The overall frequency of the respiratory symptoms assessed was 27.6%. This frequency varied 106 according to e-cigarette use categorization: it was highest for those reporting as someday current users and 107 108 lowest for never users of e-cigarettes (44.6% and 23.3%, respectively, p-value <0.0001 for differences in at least one category) (Table 1). 109

110

			garette User categ	ory N (%)*		
		Current every day C	Current some days	Former	Never	p-value
Age (median and IQR)		29(23-36)	28 (22-36)	(25- 3036)	34(27-39))
Age (in years, categories)	18-34	315(73.1)	539(74.9)	2868 (72.3)	6648(59.1)	< 0.001
	35-44	134 (26.9)	220(25.1)	1406(27.7)	5949 (40.9)	
Sex	Male	309 (72.7)	437(60.5)	2371 (58.9)	5574 (45.0)	0.002
	Female	140(27.3)	322 (39.5)	1903 (41.1)	7019(55.0)	
Race/ethnicity	White	359(79.4)	525 (65.5)	2980(63.8)	7632(48.9)	< 0.001
	Black	13 (3.2)	66(13.0)	390(11.3)	1745(18.7)	
	Hispanic	34(7.2)	105(16.0)	580(17.6)	2283 (24.6)	
	Other	43 (10.2)	63 (5.5)	324(7.2)	937 (7.7)	
Marital Status	Married	187 (40.6)	264 (35.9)	1714(38.1)	6767 (50.6)	< 0.001
	Unmarried	258 (59.4)	493 (64.1)	2538(61.9)	5752 (49.4)	
Employment Status	Employed	317 (72.6)	466 (58.2)	3028 (69.8)	9071 (70.5)	0.001
	Unemployed	54(10.1)	139(20.3)	616(14.0)	1821 (15.5)	
	Student	44(12.7)	96(15.8)	362(11.5)	1018(10.7)	
	Unable to Work	29(4.6)	48 (5.4)	215 (4.4)	473 (3.0)	
Education achievement	Up to high school	27(8.8)	75(16.6)	345(12.4)	1029(12.4)	< 0.001
	≥High school/GED	172 (43.2)	307(41.3)	1341 (31.9)	3133 (27.3)	
	\leq 3 years of college	173 (38.5)	269 (33.8)	1558 (39.2)	3469 (31.8)	
	> 4 years of college	75 (9.5)	108(8.3)	1023 (16.5)	4933 (28.5)	
Annual family income (\$)	<15,000	33 (7.9)	78(13.7)	364 (8.9)	972 (9.8)	0.001
	15,000-25,000	84(23.1)	181 (28.3)	767 (22.7)	1833(19.5)	
	25,000-35,000	59 (9.5)	76(11.3)	470(12.3)	1112(11.3)	
	35,000-50,000	68 (20.2)	89(17.3)	566(15.1)	1539(14.3)	
	>50,000	144 (39.2)	194 (29.3)	1488 (41.0)	5342 (45.1)	
Health insurance status	Insured	363 (80.0)	584(71.5)	3391 (76.8)	10379(79.0)	0.017
	Uninsured	83 (20.0)	163 (28.5)	857 (23.2)	2120(21.0)	
Exercised in past 30 days	Yes	337 (70.5)	585 (80.3)	3208 (75.6)	9614(75.8)	0.160
	No	110(29.5)	173 (19.7)	1058 (24.4)	2967 (24.2)	
Cigarette smoker status	Current	133 (29.4)	434 (53.4)	1838 (42.2)	1092(7.7)	< 0.001
	Former	225 (46.2)	105(14.5)	927 (20.5)	6094(12.0)	
	Never	86(24.4)	217(32.1)	1486(37.3)	9749 (80.2)	
History of asthma	Yes	80(16.4)	173 (24.3)	836(19.8)	1613(12.9)	< 0.001
	No	368 (83.6)	580(75.7)	3425 (80.2)	10946(87.1)	
History of COPD	Yes	19(3.5)	65(7.6)	231 (4.7)	292(2.5)	< 0.001
	No	429 (96.5)	687 (92.4)	4026(95.3)	12276(97.5)	
Report of respiratory symptoms*	** Yes	159 (32.6)	320 (44.6)	1627 (36.3)	2882(23.3)	< 0.0001
	No	290(67.4)	439 (55.4)	2647 (63.7)	9715(76.7)	

*Variables are reported as absolute count and % unless specified. **Symptoms were self-reported and included cough, phlegm production, or shortness of breath. GED- general education diploma; COPD Chronic Obstructive Pulmonary Disease). P-value corresponding to difference for at least one e-cigarette use categories

111

Table 2 displays the crude and adjusted odds ratios (ORs) for participant's selected characteristics and

112 reported respiratory symptoms. In the unadjusted analyses, compared to the never users, all e-cigarette users

- 113 had significant increased odds of reporting respiratory symptoms. After controlling for confounding factors
- 114 (participant's demographic, socio-economic, behavioral -exercise and combustible cigarette use- asthma and
- 115 COPD status), the associations were attenuated and significant only for those reporting some days of e-
- 116 cigarette use and for former users compared to those who never used e-cigarettes (OR 1.49; 95% CI: 1.06-
- 117 2.11and OR 1.29; 95% CI: 1.07-1.55, respectively). Other variables were also found independently associated
- 118 with the occurrence of respiratory symptoms; Females, Blacks, those with lower education, being unable to
- 119 work, family annual income lower than 50,000, being a current smoker, having no exercise reported in the
- past 30 days, and reporting asthma were associated with higher odds for respiratory symptoms in the adjusted
- analyses.

Characteristics	Unadjusted		Adjusted		
		OR (95% Čľ)	p-value	OR (95% ČI)	p-value
E-cigarette Use	Never	Reference	-	Reference	•
-	Current - every day	1.59 (CI 1.15-2.21)	0.005	1.41 (CI 0.96-2.08)	0.080
	Current - some days	2.65 (CI 2.04-3.46)	< 0.001	1.49 (CI 1.06-2.11)	0.022
	Former user	1.88 (CI 1.64-2.16)	< 0.001	1.29 (CI 1.07-1.55)	0.009
Age (Years)	35-44	Reference		Reference	
	18-34	1.04 (CI 0.92-1.17)	0.581	0.97 (CI 0.83-1.14)	0.754
Sex	Female	1.23 (CI 1.09-1.38)	0.001	1.27 (CI 1.08-1.48)	0.003
Race	White	Reference		Reference	
	Black	1.19 (CI 1.00-1.41)	0.054	1.26 (CI 1.01-1.59)	0.043
	Hispanic	0.86 (CI 0.73-1.01)	0.066	0.87 (CI 0.70-1.07)	0.187
	Other	0.89 (CI 0.70-1.12)	0.316	1.07 (CI 0.77-1.47)	0.699
Marital	Married	Reference		Reference	
	Unmarried	1.36 (CI 1.21-1.54)	< 0.001	1.09 (CI 0.93-1.28)	0.262
Employment Status	Employed	Reference		Reference	
	Unemployed	1.36 (CI 1.15-1.60)	< 0.001	1.17 (CI 0.93-1.46)	0.179
	Unable to Work	4.26 (CI 3.27-5.56)	< 0.001	2.47 (CI 1.76-3.48)	< 0.001
Education achievement	> 4 years of college	Reference		Reference	
	Less than high school	2.94 (CI 2.39-3.60)	< 0.001	1.72 (CI 1.28-2.30)	< 0.001
	High school/GED	2.28 (CI 1.95-2.67)	< 0.001	1.41 (CI 1.15-1.74)	0.001
	≤ 3 years of college	2.04 (CI 1.74-2.38)	< 0.001	1.46 (CI 1.21-1.76)	< 0.001
Annual family income (\$)	>50,000	Reference		Reference	
	<15,000	2.67 (CI 2.13-3.36)	< 0.001	1.54 (CI 1.14-2.08)	0.005
	15,000-25,000	2.26 (CI 1.89-2.69)	< 0.001	1.53 (CI 1.23-1.91)	< 0.001
	25,000-35,000	1.61 (CI 1.30-2.00)	< 0.001	1.27 (CI 0.99-1.62)	0.060
	35,000-50,000	1.85 (CI 1.50-2.27)	< 0.001	1.51 (CI 1.21-1.88)	< 0.001
Health insurance status	Insured	Reference		Reference	
	Uninsured	1.20 (CI 1.04-1.39)	0.014	0.89 (CI 0.73-1.08)	0.237
No exercise in past 30 days		1.59 (CI 1.39-1.82)	< 0.001	1.41 (CI 1.20-1.67)	< 0.001
Cigarette Smokers status	Never	Reference		Reference	
	Current	3.15 (2.72-3.66)	< 0.001	1.99 (CI 1.62-2.44)	< 0.001
	Former	1.24 (CI 1.04-1.48)	0.015	1.03 (CI 0.83-1.28)	0.791
History of Asthma		3.22 (CI 2.76-3.77)	< 0.001	2.63 (CI 2.18-3.17)	< 0.001
History of COPD		0.22 (CI 0.14-0.34)	< 0.001	0.42 (CI 0.26-0.69)	0.001

BRFSS- Behavior Risk Factor Surveillance System; OR – odds ratio; CI – confidence interval. Adjusted model included all variables sown in the table

To study potential interactions, further analyses were conducted assessing the association between e-122 cigarette use, and respiratory symptoms occurrence in participants who were never smokers. The absolute 123 number of participants who never smoked combustible cigarettes and were 86, 217, 1486, and 9749 for 124 current every day, current some days, former, and never e-cigarette users, respectively. In this analysis, the 125 only significant increased odds for respiratory symptoms were found for former e-cigarette users compared to 126 never users (supplemental table 1). Lastly, exclusion of participants with prior history of asthma and COPD 127 did not affect the estimates of the associations reported for e-cigarette and respiratory symptoms compared to 128 the analyses where those conditions were adjusted for (supplemental table 2). 129

130 Discussion

Our data revealed that 2.5% and 4.2% of the sample subjects were *every day* or *some days* e-cigarette users, respectively. Overall, respiratory symptoms (cough, phlegm production, or shortness of breath) were reported in approximately 28% of the sample, a much higher frequency than those symptoms previously reported in another research. (9-11) Compared to never users, e-cigarette use was associated with up to 50% increased odds of respiratory symptoms; the highest odds were found for those using some day, followed by former users of e-cigarette.

While previous research demonstrated that even short-term exposure to e-cigarettes and their toxic 137 compounds produced cough and phlegm in healthy individuals and individuals with a history of asthma,⁷ most 138 of the previous cross-sectional and longitudinal studies in US adults that were published, assessed the 139 detrimental effects of e-cigarettes focusing on outcomes such as asthma and COPD occurrence (12,13,15,17). 140 Our results for someday e-cigarette users suggesting a 49% increase in odds for the outcome, a composite of 141 cough, phlegm production, or shortness of breath, were consistent in magnitude with the previous studies, 142 despite assessing associations independently of COPD, asthma status, and demographic, socio-economic, and 143 clinical characteristics. For instance, in the meta-analyses reported in the integrative review published in 2021 144

145 by Wills et al, the pooled odds of asthma and COPD were 39% (OR=1.39, 95% CI 1.28-1.51) and 49% (OR1.49, 95% CI=1.36-1.65) higher, respectively, for e-cigarette users compared to never users (12). A less 146 marked increase in the odds of cough or phlegm has also been reported in Chinese adolescents in 2012-2013, 147 with e-cigarette users having 1.28 times higher odds to develop symptoms compared to non-users (regardless 148 of other combustible smoking habits). (11) Our results suggest that increases symptoms occur, and are 149 independent of asthma and COPD diagnosis. We also attempted to further assess for potential gradient in the 150 risk according to the frequency of e-cigarette use and our findings indicate that - while for current everyday 151 users the magnitude of the association seemed like the one found for some day users - results were no longer 152 significant after adjustments. It is possible that the smaller number of participants (about 40% less than some 153 days users) might have contributed to the lack of statistical significance. Prospective studies including larger 154 number of e-cigarette users are needed to better understand causality better, and to define whether a dose-155 response gradient exists for the risk of e-cigarettes use and respiratory symptoms. 156

E-cigarettes are designed to deliver nicotine throughout the body, without the combustion of tobacco. 157 Through inhalation of water vapor to the lungs, numerous toxic compounds like those found within 158 conventional cigarettes are released within the body. Examples of these compounds are aldehvdes 159 (formaldehyde and acrolein) and e-liquids (propylene glycol and glycerol). (7,8,18) Overtime, these 160 chemicals cause an elevated mucin concentration and result in failed mucus transport, hallmarks seen in 161 patients of COPD (Chronic Obstructive Pulmonary Disease). The chemicals within e-cigarettes also stimulate 162 neutrophils, resulting in the release of myeloperoxidase (MPO), neutrophil elastase (NE), and other granular 163 proteins. The amount of proteins released in e-cigarettes is double to what was described for conventional 164 cigarettes, and it causes massive structural damage to airways. (19) These changes could explain potential 165 mechanism that contribute to the common symptoms of chronic cough, phlegm, and shortness of breath 166 observed in e-cigarette users. 167

This study large sample size and the use of systematically collected and comprehensive information 168 from participants from multiple states contribute to increase study's generalizability when representing the 169 adult population in the US. There are some limitations inherent to the cross-sectional and self-reported nature 170 of the survey, and they should be discussed. First, we lack detailed information on the timing when e-cigarette 171 and the symptoms occurred. The BRFSS survey inquired about cough and phlegm occurring in the three 172 months preceding the survey, while e-cigarettes use status referred to the time of the survey. Therefore, the 173 extent of which potential reverse causality accounts for the association described is unknown, and prospective 174 studies are warranted. Furthermore, given the responses were based on self-report, misclassifications of both 175 exposure to e-cigarettes and occurrence of symptoms are possible. While we do not have evidence to help us 176 to estimate the directionality of the bias, we believe that both the frequency of symptoms and of e-cigarettes 177 would be underreported, thus, most likely biasing the association towards the null hypothesis. 178 In conclusion, our results also suggest that e-cigarettes might increase the risk of detrimental 179 respiratory symptoms, but the dose-effect relationship is yet to be confirmed with more accurate assessment 180

of e-cigarette exposure levels. Therefore, our study adds to the growing body of literature suggesting that e cigarettes are not safe alternatives for smoking cessation interventions.

183 References

(1) Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. Electronic
 cigarettes for smoking cessation. Cochrane Database Syst Rev 2021 Apr 29;4:CD010216.

186 (2) Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: a step

- forward or a repeat of past mistakes? J Public Health Policy 2011 Feb;32(1):16-31.
- 188 (3) Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C. Success rates with nicotine personal
- vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health
- 190 2014 Nov 8;14:1159-2458-14-1159.

- 191 (4) Du Y, Liu B, Xu G, Rong S, Sun Y, Wu Y, et al. Association of Electronic Cigarette Regulations
- 192 With Electronic Cigarette Use Among Adults in the United States. JAMA Netw Open 2020 Jan
- **193** 3;3(1):e1920255.
- 194 (5) Mirbolouk M, Charkhchi P, Kianoush S, Uddin SMI, Orimoloye OA, Jaber R, et al. Prevalence
- and Distribution of E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System,
- **196** 2016. Ann Intern Med 2018 Oct 2;169(7):429-438.
- 197 (6) Gentzke AS, Wang TW, Jamal A, Park-Lee E, Ren C, Cullen KA, et al. Tobacco Product Use
- Among Middle and High School Students United States, 2020. MMWR Morb Mortal Wkly Rep
 2020 Dec 18;69(50):1881-1888.
- 200 (7) Allen JG, Flanigan SS, LeBlanc M, Vallarino J, MacNaughton P, Stewart JH, et al. Flavoring
- 201 Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products,
- Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes. Environ Health Perspect 2016
- **203** Jun;124(6):733-739.
- (8) Armendariz-Castillo I, Guerrero S, Vera-Guapi A, Cevallos-Vilatuna T, Garcia-Cardenas JM,
- 205 Guevara-Ramirez P, et al. Genotoxic and Carcinogenic Potential of Compounds Associated with
- Electronic Cigarettes: A Systematic Review. Biomed Res Int 2019 Dec 19;2019:1386710.
- 207 (9) McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, et al. Electronic
- Cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med 2017 Apr
- 209 15;195(8):1043-1049.
- 210 (10) Tackett AP, Keller-Hamilton B, Smith CE, Hebert ET, Metcalf JP, Queimado L, et al. Evaluation
- of Respiratory Symptoms Among Youth e-Cigarette Users. JAMA Netw Open 2020 Oct
- 212 1;3(10):e2020671.
- 213 (11) Wang MP, Ho SY, Leung LT, Lam TH. Electronic Cigarette Use and Respiratory Symptoms in
- Chinese Adolescents in Hong Kong. JAMA Pediatr 2016 Jan;170(1):89-91.

- 215 (12) Wills TA, Soneji SS, Choi K, Jaspers I, Tam EK. E-cigarette use and respiratory disorders: an
- 216 integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J
- 217 2021 Jan 21;57(1):10.1183/13993003.01815-2019. Print 2021 Jan.
- 218 (13) Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Dardari ZA, et al. The association
- 219 between e-cigarette use and asthma among never combustible cigarette smokers: behavioral risk factor
- surveillance system (BRFSS) 2016 & 2017. BMC Pulm Med 2019 Oct 16;19(1):180-019-0950-3.
- 221 (14) Mirbolouk M, Charkhchi P, Orimoloye OA, Uddin SMI, Kianoush S, Jaber R, et al. E-Cigarette
- 222 Use Without a History of Combustible Cigarette Smoking Among U.S. Adults: Behavioral Risk
- Factor Surveillance System, 2016. Ann Intern Med 2019 Jan 1;170(1):76-79.
- (15) Bhatta DN, Glantz SA. Association of E-Cigarette Use With Respiratory Disease Among Adults:
- A Longitudinal Analysis. Am J Prev Med 2020 Feb;58(2):182-190.
- 226 (16) Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System.
- Aug 30th, 2021; Available at: https://www.cdc.gov/brfss/. Accessed 09/21/2021.
- 228 (17) Barrameda R, Nguyen T, Wong V, Castro G, Rodriguez de la Vega P, Lozano J, et al. Use of E-
- Cigarettes and Self-Reported Lung Disease Among US Adults. Public Health Rep 2020
- 230 Nov/Dec;135(6):785-795.
- 231 (18) Thirion-Romero I, Perez-Padilla R, Zabert G, Barrientos-Gutierrez I. Respiratory Impact of
- Electronic Cigarettes and "Low-Risk" Tobacco. Rev Invest Clin 2019;71(1):17-27.
- 233 (19) Reidel B, Radicioni G, Clapp PW, Ford AA, Abdelwahab S, Rebuli ME, et al. E-Cigarette Use
- 234 Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation
- and Altered Mucin Secretion. Am J Respir Crit Care Med 2018 Feb 15;197(4):492-501.

236 Acknowledgments

- 237 We thank the Behavior Risk Factor Surveillance System (BRFSS) working group and the survey
- 238 participants for their contribution.

	medRxiv preprint doi: https://doi.org/10.1101/2022.05.30.22275770; this version posted May 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	